Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML

NCT03258931 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

214

Enrollment

INDUSTRY

Sponsor class

Conditions

Newly Diagnosed FLT3 Mutated AML

Interventions

DRUG: Crenolanib
DRUG: Midostaurin
DRUG: Cytarabine
DRUG: Duanorubicin

Sponsor

Arog Pharmaceuticals, Inc.